Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP-R-ESC: Rituximab Schedules with CHOP-14 in Elderly Lymphoma
NCT00290667Phase 2Completed
- Sponsor
- German High-Grade Non-Hodgkin Lymphoma Study Group
- Start
- Feb 2004
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of rituximab in aggressive B-cell lymphoma (2 arms), sponsored by German High-Grade Non-Hodgkin Lymphoma Study Group. Primary endpoints: Pharmacokinetic profile and Safety and toxicity profile. Started Feb 2004; status: completed.
02
Drugs
rituximab
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT00290667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290667.